Skip to main content
. Author manuscript; available in PMC: 2022 Sep 27.
Published in final edited form as: J Biomed Nanotechnol. 2019 Nov 1;15(11):2229–2239. doi: 10.1166/jbn.2019.2859

Figure 4. CTLA-4 Nb16 promoted the tumor cell killing effects of CD8+ lymphocytes.

Figure 4.

(A) Comparison of cell killing effects of CD8+ T lymphocytes induced by indicated treatments on HepG2 in different E:T raitos of 5:1, 10:1 and 20:1. DHFC+CTLA-4 Nb16 enhanced cytotoxic T cell killing function on target HepG2 cells. (B) Comparison of cell killing effects of CD8+ T lymphocytes induced by indicated treatments on MCF-7. It had weaker killing effect on MCF-7 than HepG2. Data are means ± SD, n = 3.